Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review

J Child Neurol. 2001 Feb;16(2):113-8. doi: 10.1177/088307380101600209.


Over the last several years, botulinum toxin type A has gained widespread use for the management of focal spasticity in children with cerebral palsy. To assess the current patterns of botulinum toxin type A use in the clinical setting, the dose, muscles injected, age at injection, and interval between injections of botulinum toxin type A treatments were examined in a retrospective chart review of children with cerebral palsy (N = 270) over a 2-year period at three major treatment centers. The average dose of botulinum toxin type A across the three centers ranged from 7.7 to 10.8 U/kg body weight, and the average total amount of botulinum toxin type A injected at a single visit ranged from 154 to 205 U. The majority of botulinum toxin type A injections were to the muscles to the lower limbs. The average age at first injection was 6.2 years, and the average interval between injections ranged from 134 to 199 days.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Botulinum Toxins, Type A / therapeutic use*
  • Cerebral Palsy / drug therapy*
  • Child
  • Child, Preschool
  • Clinical Protocols
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Infant
  • Injections, Intramuscular
  • Male
  • Medical Records
  • Neuromuscular Agents / therapeutic use*
  • Retrospective Studies
  • Treatment Outcome


  • Neuromuscular Agents
  • Botulinum Toxins, Type A